47.16
0.65 (1.40%)
| Previous Close | 46.51 |
| Open | 46.96 |
| Volume | 492,606 |
| Avg. Volume (3M) | 853,159 |
| Market Cap | 2,704,123,904 |
| Price / Earnings (Forward) | 20.16 |
| Price / Sales | 4.07 |
| Price / Book | 2.53 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 9.27% |
| Operating Margin (TTM) | -4.67% |
| Diluted EPS (TTM) | 1.11 |
| Quarterly Revenue Growth (YOY) | 4.30% |
| Quarterly Earnings Growth (YOY) | 1,204.50% |
| Total Debt/Equity (MRQ) | 3.13% |
| Current Ratio (MRQ) | 2.44 |
| Operating Cash Flow (TTM) | 164.15 M |
| Levered Free Cash Flow (TTM) | 138.80 M |
| Return on Assets (TTM) | 2.76% |
| Return on Equity (TTM) | 6.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Supernus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.10 |
|
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 4.11% |
| % Held by Institutions | 109.15% |
| 52 Weeks Range | ||
| Median | 55.00 (16.62%) | |
| Total | 1 Hold | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 19 Dec 2025 | 55.00 (16.62%) | Hold | 51.48 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BARLOW CARROLEE | 53.30 | - | 4,475 | 238,518 |
| BHATT PADMANABH P. | 53.30 | 53.30 | 1,544 | 82,295 |
| GEMAYEL GEORGES | 53.30 | - | 4,475 | 238,518 |
| HUDSON FREDERICK M. | 53.30 | - | 4,475 | 238,518 |
| MOTTOLA FRANK | 53.30 | 53.30 | 1,484 | 79,097 |
| NEWHALL CHARLES W III | 53.30 | - | 4,475 | 238,518 |
| RUBIN JONATHAN | 53.30 | 53.30 | 1,482 | 78,991 |
| SENSENIG BETHANY | - | 51.35 | -4,475 | -229,791 |
| Aggregate Net Quantity | 17,935 | |||
| Aggregate Net Value ($) | 964,662 | |||
| Aggregate Avg. Buy ($) | 53.30 | |||
| Aggregate Avg. Sell ($) | 52.81 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| GEMAYEL GEORGES | Director | 24 Feb 2026 | Acquired (+) | 4,475 | 53.30 | 238,518 |
| RUBIN JONATHAN | Officer | 24 Feb 2026 | Acquired (+) | 3,125 | 53.30 | 166,563 |
| RUBIN JONATHAN | Officer | 24 Feb 2026 | Disposed (-) | 1,643 | 53.30 | 87,572 |
| MOTTOLA FRANK | Officer | 24 Feb 2026 | Acquired (+) | 3,125 | 53.30 | 166,563 |
| MOTTOLA FRANK | Officer | 24 Feb 2026 | Disposed (-) | 1,641 | 53.30 | 87,465 |
| BHATT PADMANABH P. | Officer | 24 Feb 2026 | Acquired (+) | 3,125 | 53.30 | 166,563 |
| BHATT PADMANABH P. | Officer | 24 Feb 2026 | Disposed (-) | 1,581 | 53.30 | 84,267 |
| BARLOW CARROLEE | Director | 24 Feb 2026 | Acquired (+) | 4,475 | 53.30 | 238,518 |
| HUDSON FREDERICK M. | Director | 24 Feb 2026 | Acquired (+) | 4,475 | 53.30 | 238,518 |
| NEWHALL CHARLES W III | Director | 24 Feb 2026 | Acquired (+) | 4,475 | 53.30 | 238,518 |
| GEMAYEL GEORGES | Director | 23 Feb 2026 | Option execute | 15,000 | - | - |
| SENSENIG BETHANY | Director | 19 Feb 2026 | Automatic sell (-) | 4,475 | 51.35 | 229,791 |
| SENSENIG BETHANY | Director | 19 Feb 2026 | Option execute | 4,475 | - | - |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 03 Dec 2025 | Announcement | Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |